ReviewCancer discovery2019
Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma.
Review in Cancer discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Cellular Origins and Context-Dependent Prognostic Effects of Lactate Metabolism Genes Reveal Novel Molecular Subtypes in Gastric Cancer.Current issues in molecular biology · 2026Article
- The INSPECTOR study: enhanced feasibility for clinical translation of a multi-cancer early detection method based on enzyme-assisted high signal-to-noise ratio sequencing of methylated circulating tumor DNA.Cancer communications (London, England) · 2025Article
- Harnessing technologies to unravel gastric cancer heterogeneity.Trends in cancer · 2025Review
- Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification.Molecular cancer therapeutics · 2025Article
- Practical management of oligometastatic gastric cancer.ESMO gastrointestinal oncology · 2024Review
- Clinical glycoproteomics: methods and diseases.MedComm · 2024Review
- International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape : Bertinoro Workshop, November 2022.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024Article
- Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers.The oncologist · 2024Article
- Transcription factor EHF interacting with coactivator AJUBA aggravates malignancy and acts as a therapeutic target for gastroesophageal adenocarcinoma.Acta pharmaceutica Sinica. B · 2024Article
- Clinical Significance of Disulfidptosis-related Genes and Functional Analysis in Gastric Cancer.Journal of Cancer · 2024Article
- Clinically conserved genomic subtypes of gastric adenocarcinoma.Molecular cancer · 2023Article
- Discovery and Initial Characterization of Long Intergenic Noncoding RNAs Associated With Esophageal Adenocarcinoma.Gastroenterology · 2023Article
- Neutrophil extracellular traps induced by the hypoxic microenvironment in gastric cancer augment tumour growth.Cell communication and signaling : CCS · 2023Article
- MiR-200/183 family-mediated module biomarker for gastric cancer progression: an AI-assisted bioinformatics method with experimental functional survey.Journal of translational medicine · 2023Article
- The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma.Journal of experimental & clinical cancer research : CR · 2023Article
- Emerging targets in gastroesophageal adenocarcinoma: what the future looks like.Therapeutic advances in medical oncology · 2023Review
- Article
- Molecular evolutionary process of advanced gastric cancer during sequential chemotherapy detected by circulating tumor DNA.Journal of translational medicine · 2022Article
- Progress in neoadjuvant therapy for gastric cancer.Oncology letters · 2022Review
- Mapping the genomic diaspora of gastric cancer.Nature reviews. Cancer · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Gastroesophageal adenocarcinomas (GEA) are devastating diseases with stark global presence. Over the past 10 years, there have been minimal improvements in treatment approach despite numerous clinical trials. Here, we review recent progress toward understanding the molecular features of these cancers and the diagnostic and therapeutic challenges posed by their intrinsic genomic instability and heterogeneity. We highlight the potential of genomic heterogeneity to influence clinical trial outcomes for targeted therapies and emphasize the need for comprehensive molecular profiling to guide treatment selection and adapt treatment to resistance and genomic evolution. Revising our clinical approach to GEA by leveraging genomic advances will be integral to the success of current and future treatments, especially as novel targets become therapeutically tractable. SIGNIFICANCE: GEAs are deadly cancers with few treatment options. Characterization of the genomic landscape of these cancers has revealed considerable genetic diversity and spatial heterogeneity. Understanding these fundamental properties of GEA will be critical for overcoming barriers to the development of novel, more effective therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.